Search
Research
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccineThe efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with HPV...
Research
A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.This publication is a systematic analysis of all Group A Streptococcus M protein variants, to assist in the development of a vaccine.
Research
Invasive group A streptococcal infection in the Northern Territory, Australia: Case report and review of the literatureThis review article presents the case of infant Aboriginal twins with invasive group A streptococcal infection complicated by streptococcal toxic shock...
Research
Reduction in disparity for pneumonia hospitalisations between Australian indigenous and non-Indigenous childrenIn the 1990s pneumonia hospitalisation rates in Western Australia (WA) were 13 times higher in Indigenous children than in non-Indigenous children...
Research
Prevalence of and risk factors for human rhinovirus infection in healthy aboriginal and non-aboriginal western australian childrenHuman rhinovirus (HRV) species C (HRV-C) have been associated with frequent and severe acute lower respiratory infections and asthma in hospitalized children.
Research
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthyNeisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent...
Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.
Research
FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months OldEvidence-based recommendations exist for early discharge (before 48 h) of young infants with fever without source (FWS) at low risk of serious bacterial infections (SBIs). However, concerns regarding the applicability of international data to local contexts may hinder implementation. We aimed to describe the local epidemiology of FWS and evaluate a newly implemented risk-stratification guideline to support practice change.
Research
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY VaccineA MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.